Allergan (AGN) Tops Q2 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P, Nasdaq drop on semiconductor selloff as AI spending concerns mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Needham Starts NeoVolta (NEOV) at Buy
Piper Jaffray Remains Sidelined on Allergan (AGN) Following Mixed 2Q
August 9, 2016 9:08 AM EDTPiper Jaffray maintained a Neutral rating on Allergen (NYSE: AGN), and cut the price target to $227.00 (from $236.00), following the company's 2Q earnings report. AGN reported non-GAAP diluted EPS of $3.35 on revenue of $3.68B, compared to Street estimates of $3.33 and $3.97B, respectively.
Analyst David Amsellem commented, "Allergan... More
Allergan (AGN) CEO Says Not Focused on or Looking at Large Deals (BIIB)
August 8, 2016 9:21 AM EDTAllergan's (NYSE: AGN) CEO said the company isn't focused on or looking at large deals.
Traders are watching shares of rumored target Biogen (NASDAQ: BIIB) following the comments.
... MoreAllergan (AGN) August weekly volatility flat into Q2 and outlook
August 8, 2016 6:18 AM EDTAllergan (NYSE: AGN) August weekly call option implied volatility is at 35, August and September is at 28; compared to its 52-week range of 20 to 53 into the expected release of Q2 results today.
... More